Skip to main content

The z-profile study: A multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in canadian adult patients with chronic hepatitis c

Publication ,  Journal Article
Tam, E; Tremblay, J; Fraser, C; Conway, B; Ramji, A; Borgia, S; Tsoi, K; Yoshida, EM; Rajendran, B; Macphail, G; Wong, A; Cooper, C; Patel, K ...
Published in: Canadian Liver Journal
January 1, 2020

BACKGROUND: Canada was the first country to approve elbasvir/grazoprevir (EBR/GZR) for the treatment of chronic HCV infection for genotypes 1 and 4 with or without ribavirin and genotype 3 with sofosbuvir, with no recommendation for baseline resistance testing. The aim of this study was to describe the effectiveness of EBR/ GZR and the profile of patients selected for treatment in a Canadian real-world setting. METHODS: This multicenter retrospective study of HCV-infected patients treated with EBR/GZR took place among selected Canadian health care providers, with no exclusion criteria. Primary outcome measures included parameters associated with patient profile and sustained virologic response at 12 weeks (SVR12) and 24 weeks after treatment. RESULTS: A total of 408 patients were included; 244 had available SVR12 information (per-protocol population [PP]). Genotype distribution included 1a (54.7%), 1b (17.2%), 3 (11.8%), 4 (10.0%), and other (6.4%). The majority (88.7%) of participants were treated for 12 weeks without ribavirin. Fifty-nine (14.5%) participants, predominantly with genotype 1a (49/59) infection, were tested for baseline resistance-associated substitutions (bRAS). SVR12 was achieved by 95.9% of the PP. In an exploratory analysis assessing potential predictors of SVR12, participants who had undergone bRAS testing (OR 0.14, 95% CI 0.03–0.64) and participants who had undergone liver transplant (OR 0.05, 95% CI 0.00–0.68) had significantly lower odds of achieving SVR12. CONCLUSIONS: This study supports the real-world effectiveness of EBR/GZR—including a broad range of genotypes and diverse fibrosis stages—in the absence of bRAS testing and in special populations.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Canadian Liver Journal

DOI

EISSN

2561-4444

Publication Date

January 1, 2020

Volume

3

Issue

3

Start / End Page

251 / 262
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tam, E., Tremblay, J., Fraser, C., Conway, B., Ramji, A., Borgia, S., … Trepanier, J. B. (2020). The z-profile study: A multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in canadian adult patients with chronic hepatitis c. Canadian Liver Journal, 3(3), 251–262. https://doi.org/10.3138/canlivj-2019-0029
Tam, E., J. Tremblay, C. Fraser, B. Conway, A. Ramji, S. Borgia, K. Tsoi, et al. “The z-profile study: A multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in canadian adult patients with chronic hepatitis c.” Canadian Liver Journal 3, no. 3 (January 1, 2020): 251–62. https://doi.org/10.3138/canlivj-2019-0029.
Tam, E., et al. “The z-profile study: A multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in canadian adult patients with chronic hepatitis c.” Canadian Liver Journal, vol. 3, no. 3, Jan. 2020, pp. 251–62. Scopus, doi:10.3138/canlivj-2019-0029.
Tam E, Tremblay J, Fraser C, Conway B, Ramji A, Borgia S, Tsoi K, Yoshida EM, Rajendran B, Macphail G, Wong A, Cooper C, Patel K, Puglia M, Stewart K, Trottier B, Deshaies L, Doucette K, Ghali P, Lee SS, Halsey-Brandt J, Trepanier JB. The z-profile study: A multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in canadian adult patients with chronic hepatitis c. Canadian Liver Journal. 2020 Jan 1;3(3):251–262.

Published In

Canadian Liver Journal

DOI

EISSN

2561-4444

Publication Date

January 1, 2020

Volume

3

Issue

3

Start / End Page

251 / 262